|
¸¶ÀϽºÅæ¼Ä¡ |
Oncology Brand Manager(Æó¾Ï½ÅÁ¦Ç°)/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
5³â¡è |
ä¿ë½Ã |
12.12 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
PR Specialist/Global¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
±¤°í/È«º¸/PR/»çº¸ |
2³â¡è |
ä¿ë½Ã |
11.02 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
RA Specialist/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
1³â¡è |
ä¿ë½Ã |
11.02 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
ISS Specialist/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
09.08 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
RA Specialist(Á¤±ÔÁ÷)/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
3³â¡è |
ä¿ë½Ã |
12.12 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
È£Èí±âMSL/Global¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
1³â¡è |
ä¿ë½Ã |
12.01 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
MSL(Oncology)/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
1³â¡è |
ä¿ë½Ã |
11.02 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
´ç´¢ÆÀ MSL Manager/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
5³â¡è |
ä¿ë½Ã |
03.11 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
MSL(Oncology)/À¯¸í¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
08.03 |
|
|
DREAMHR |
°Ç°º¸Á¶½ÄÇ° Çмú¸¶ÄÉÆà ÆÀÀå
¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
°Ç°º¸Á¶½ÄÇ°/ÈÀåÇ°¿µ¾÷ |
5³â¡è |
ä¿ë½Ã |
07.05 |
|
|
¿¡ÀÌÄ¡¾ËŬ¸¯ |
Á¦¾à»ç ÇØ¿Ü¿µ¾÷ Â÷ºÎÀå±Þ ä¿ë
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.11 |
|
|
(ÁÖ)¿¡ÄÚ½áÄ¡ |
¿Ü±¹°èÁ¦¾àȸ»ç / Product Manager
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
3³â¡è |
ä¿ë½Ã |
06.13 |
|
|
(ÁÖ)¿¡ÄÚ½áÄ¡ |
¿Ü±¹°èÁ¦¾àȸ»ç/Pricing&Reimbursement Specialist
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
3³â¡è |
ä¿ë½Ã |
06.13 |
|
|
Çì´Ï¾Ø¸ÓÄÚÀÌ |
Pharmacovigilance (MI) Specialist / Regulatory Affairs
¼¿ï °³²±¸, ¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
03.14 |
|
|
(ÁÖ)À¯´ÏÄÚ½á¾îÄ¡ |
[±¹³» ¹ÙÀÌ¿À Á¦¾àȸ»ç] ±Û·Î¹ú »ç¾÷°³¹ß ÀÓ¿ø
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÇìµåÇåÅÍ |
17³â¡è |
ä¿ë½Ã |
03.28 |
|